Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | HPGD | P15428 | 7/20 | 0.56 |
| ▸ | TP53 | P04637 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | BRD2 | P25440 | 1/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10834901 | 0.84 | TP53 (0.46) | KDM4ESMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL10835842 | 0.83 | TP53 (0.45) | KDM4ESMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL10054151 | 0.83 | KDM4E (0.69) | KDM4ESMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL8111957 | 0.81 | KDM4E (0.55) | KDM4ESMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL11166490 | 0.81 | ALDH1A1 (0.57) | KDM4ESMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL8282012 | 0.81 | KDM4E (0.71) | KDM4ESMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL1186459 | 0.80 | MAOB (0.51) | KDM4ESMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL12896087 | 0.79 | PIM1 (0.52) | KDM4ESMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL25469661 | 0.78 | SMN1; SMN2 (0.43) | KDM4ESMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL12171427 | 0.78 | ALDH1A1 (0.67) | KDM4ESMN1; SMN2ALDH1A1HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932390-B2 | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2038288-B1 | NOVEL 4-AMINO-3-(-AZOLYL-PHENOXYMETHYL)-THIENOÝ3,2¨PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-11-24 | — | — | EP | disclosed |
| EP-2038288-A1 | NOVEL 4-AMINO-3-(-AZOLYL-PHENOXYMETHYL)-THIENOÝ3,2¨PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20080009515-A1 | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives | CHEN YI | 2008-01-10 | — | — | US | disclosed |
| WO-2008000697-A1 | NOVEL 4-AMINO-3-(-AZOLYL-PHENOXYMETHYL)-THIENO[3,2]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009515-A1 | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives | UQCRB, UQCRC2, AURKB | KDM4E 1751/4885SMN1; SMN2 4044/4885ALDH1A1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.